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The remarkable development and application of new genetic 
technologies over the past decades has been accompanied by profound changes 
in the way in which research is commercialized in the life sciences. As results, 
new varieties of commercially grown crops with improved or new traits are 
developed. Many thousands of patents which assert rights over DNA sequences 
have been granted to researchers across the public and private sector. The effects of 
many of these patents are extensive, because inventors who assert rights over DNA 
sequences obtain protection on all uses of the sequences. Extremely valuable to 
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breeders in the national agricultural research system is the ability to genotype 
their collections to get a clear picture of their diversity and how diversity could 
be enhanced through sharing and access to global collections. The issue of the 
eligibility for patenting of DNA sequences needs to be reopened. Patents that 
assert rights over DNA sequences and their uses are, in some cases, supportable, 
but in others, should be treated with great caution. Rights over DNA 
sequences as research tools should be discouraged. That the best way to 
discourage the award of such patents is by stringent application of the criteria 
for patenting, particularly utility. A more equitable, ethically – based food 
and agricultural system must incorporate concern for three accepted global 
goals: improved well being, protection of the environment and improved 
public health (particular point food from GMO). To mitigate conflict one of 
the approach to solve problem is ethical and truthful label of GM food, 
because consumers have a right to choose whether to eat genetically 
modified foods or not. Interesting examples and risks as consequences of free 
availability of genetic resources utilization, its transformation, patenting of   “new” 
organism and selling it back to the genetic resource owner are presented.  Society   
has obligations to raise levels of   nutrition and standards living by all respect to 
ethics at each step. 
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INTRODUCTION 
Over the past two or more decades, the structure of agricultural input has 
changed very rapidly - input of private sector in agriculture and food  Research and 
Development (R&D) has grown dramatically, while public-sector investment has 
remained relatively constant (SHOEMAKER et al., 2001). The use of intellectual 
property (IP),  in the form of  plant variety protection certificates and utility patent   has  
also expanded very rapidly over roughly the same time period. More than any other 
component of agricultural R&D, agricultural biotechnology exemplifies these trends 
(J.E.M. 2001). Patenting in a specific type of plant biotechnology - plant cultivars is also 
of  interest. Patents for cultivars are now issued whether or not they result from the use 
of some molecular technique such as gene insertion.  
Private firms almost completely dominate cultivar patenting. United States 
private firms are patenting far more cultivars than do non -US firms. Two crops, maize 
and soybeans, also account for most of the US utility patents on plant cultivars. 
Patents represent in Europe only a minor mechanism for technology transfer, 
access to information (publications) and various forms of capacity and institution 
building  and are important mechanisms to transfer technologies and facilitate their use 
(ECE, 1995). Few patents are relevant in potato breeding, where the private keep new 
varieties available for further breeding and claims not to seek profit from poor 
farmers in developing countries. Clearly, both governmental institutions, universities 
and private firms devote a substantial proportion of program patenting in agricultural 
biotechnology to patents that, concern biological control of pests and diseases for 
plants and animals. Intellectual property issues were and are some of the most 
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controversial in modern biotechnology (OTA, 1989; LESSER, 1991). In this report the 
short overview on contemporary research in the field of plant biotechnology and 
protecting obtained results in the form of patent  
 
BIOTECHNOLOGY 
The agricultural commons were created and nurtured by countless 
generations of breeders and seed-savers without commercial reward, and were 
bequeathed to mankind at no cost. The ancient practice of farmers and gardeners 
saving seed from their harvest for planting next season is an inalienable right. 
Seed saving  is essential to adapting plants to local conditions, especially where 
environmental degradation and global climate change processes occur.  Seed must 
not become a product that can be dealt only to breeding new varieties.   
Agricultural biotechnology may be understood as these of organisms or 
parts of an organism to make or improve products or processes in agriculture. The 
domestication of plant species and selection of desired characteristics within 
agricultural species would qualify under this definition. What biotechnology 
represents today is new knowledge about the natural processes of the DNA 
replication, breakage, ligation, and repair that has made possible a deeper 
understanding of the mechanics of cell biology and the hereditary process itself 
(MC COUCH, 2001; KONSTANTINOV et al., 1993; MLADENOVIĆ DRINIĆ et al., 2002).  
Although in agriculture the term biotechnology has been most closely associated 
with genetic manipulation at the DNA level, or genetic engineering, it may refer 
to a variety of techniques or products. These may include, for example, use of 
molecular markers in genetic improvement or more general use of genomic 
information (SMITH et al., 1987; MLADENOVIĆ DRINIĆ et al., 2004). Similarly, the 
use of enzymes for fermentation in brewing or cheese making would be early 
examples of a broadly defined food biotechnology. Genetically engineering yeast 
to modify or improve a baking process would be an example of a narrower or 
more recent definition of food biotechnology.  
The benefits that are hoped for from the biotechnology based on genetic 
engineering include: (i) increased productivity of crops, growth rates and ratio of 
plant product which could be used; (ii) increased quality of crops, including 
nutritional quality and storage properties; (iii) adaptation of plants to specific 
environmental conditions; (iv) broaden plants tolerance to stress; (v) production of 
substances in food crops and (vi) utilization of new raw materials.  Ecological and 
scientific studies to produce better crops and farming practices should lie at the 
heart of biotechnology. Future potential of genetic engineering to produce more 
nutritious and safer food than we consume now, by the breeding of new varieties of 
crops excluding the naturally occurring  toxins and carcinogens that we consume 
everyday from the food.   
Some transgenic crops still contain antibiotic resistance genes when they 
are grown (MLADENOVIĆ et al., 1991; MARTINCAN et al., 1994; KONSTANTINOV et al., 
1993., KONSTANTINOV et al., 1997; KONONOV et al., 1997).This concern lead to 
rejection of a maize with an  inserted Bt gene that control resistance to European 
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corn borer, that was being marketed  by Ciba-Geigy (COGHLAN, 1996). Studies in 
mice and rats of the protein product of the marker NPTII gene which control 
neomycin resistance found it as safe for consumption (FUCHS et al., 1993). Therefore 
particular variety of soybeans would have had to be labeled under FDA policy. 
However it has been decided to abandon development of this variety (NESTLE, 1996).  
The major concerns are ecological and have been the subject of a number 
of studies and reports (OTA, 1988, 1991; RUDELSHEIM et al., 1994). The issue has, 
and continues need to be addressed by scientific studies. Prospective effect has been 
partially controlled by the Convention on Biological Diversity, which regulates 
collecting of species after 1993 in the wild. It does not regulate the use of the 
samples from botanical gardens that were collected before this, and also it does not 
regulate the resources found in the oceans of international waters (TANGLEY, 1996). 
It covers the country of ownership, but inside countries there are also disputed claims 
to which community has rights. This new approach contrasts with the practice which 
still continues among many researchers for free exchange of materials, and there are 
unresolved ethical questions about whether one country or group can claim 
ownership of a species. Another approach would be to see them as the common 
heritage of all species and all humanity. 
GRAFF et al. (2002, 2003a, b) offer definition of agricultural biotechnology 
broader and it includes such areas as crop resources that may not have been 
developed using the techniques of molecular biology. They defined different kinds of 
technologies: resources transformation platforms and traits, and found that some 
institutions tended to combine different types of technology, dependent on the type 
of firm. On the research input side, data on investment in the agricultural 
biotechnology would be valuable (XIA and BUCCOLA 2005).Breakdown of the 
investment by technological area and other indicators of research objective would 
add even more. Unfortunately, detailed data in agricultural biotechnology are often 
either unavailable or nonexistent. 
In developing countries  plant  breeding  is  public service to support 
development  program  that  reach  near-subsistence farmers that are not likely to 
become customers of  private sector. For the most important food crops, public 
activities are at the basis of the Green Revolution and significantly contributed to 
free distribution of the half - bred materials and finished varieties. The new 
technologies may facilitate their work for poverty reduction only if they can access 
them.  
Use of the licenses for help to undeveloped countries have been used to 
make individual technologies available for research and for development. Such 
licenses are generic, rather than dealing with individual transfers, and with opening   
require explicit action and communication to facilitate actual technology transfer. 
Open-source is another model for increasing access and reducing transaction costs.  
Philosophy of innovation in networks with weak - informal - ties as opposed to a 
linear organizational structure with formal contracts would underlie an “open 
innovation system”. Despite various initiatives to promote open source strategies 
the models do not seem to gain much importance in more product oriented 
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biotechnology research (SHOEMAKER et al., 2001; GRAFF et al., 2002; 
http://www.cfra.org/resources/issue_brief_patenting.htm). 
A number of factors could explain the unprecedented increase in 
applications for patents. According to HALL (2004) the initial structural break was 
largely accounted for by firms in electrical and computing technology.  In  addition,  
other  related  technological areas, such as software and  information  technology, 
witnessed a rapid  increase of  innovation and new firm creation over much  the same  
period as the increase in patents. The new molecular and genomic tools used in 
genetically engineering plants have also vastly enhanced the enforceability of 
intellectual  property  protection by providing  new and more powerful  means of 
establishing that someone  has  illegally used  a protected  variety. It  is now possible  
definitively characterize  plants  and  seeds at  the molecular  level by establishing 
their unique “fingerprints” in a manner similar to that used for DNA profiling in 
criminal cases. It is also possible to detect the use of the protected varieties or 
genetic material in breeding new varieties (KORTUM and LEMER, 1999). 
The so-called “farmer's privilege” that allows farmers to harvest and 
legitimately use propagating material derived from the crop grown from  the original 
and  legitimately obtained  propagating  material  for subsequent cropping cycles on 
their own farm should be a right. These are the processes which maintain and 
improve local biodiversity and adaptation that will be crucial as global climate 
change arises.  
  
 PATENTING IN AGRICULTURAL BIOTECHNOLOGY  
The face of plant breeding research has changed significantly due to the 
rapid technological developments in the field of genomics and to revolutionary 
changes in the legal and policy environment in which plant scientists and breeders are 
working. 
Varieties eligible for protection are those that are new, uniform, stable (in 
the sense of reproducing their characteristics in their progeny), and distinct from 
existing varieties. Principles are: (i) only the first inventor of something patentable 
can obtain a patent; (ii) the invention must be useful; (iii) the invention must be novel; 
(iv)the patent must involve a creative step.  There are different tests for the novelty.    
Different kinds of  protection  have been available for some time. Legal   
protection of plant varieties was introduced in the United States long time before 
development of genetically engineered plants. Since 1930 a type of patent  introduced  
especially for plants, known  as  a “plant patent,”  has  been  available  from the U.S. 
Patent and Trademark Office (USPTO) in the Department of Commerce, to protect  
novel clonally propagated (i.e., asexually reproduced) plant varieties including fruit 
trees, ornamentals, and berries.  
Plant patents, like the more common and much older utility patents 
available for inventions   are currently enforceable from the date they are granted until 
20 years from the date of application. Since 1970 Plant Variety Protection Certificates 
(PVPCs) have been  available from U.S. Department of Agriculture. The term of   
protection offered under PVPC is now 20 years for most crops, 25 for trees and vines. 
200                                                                                   GENETIKA, Vol. 42, No. 1,195 -208, 2010 
Farmers are allowed to save seed of varieties protected by PVPCs for replanting their 
crops, but they cannot provide or sell those seeds to others for planting 
(http://www.genethics.org)   
It is important to note that plant  patents and  PVPCs  prevent only unlawful  
proliferation of the variety; they do not  prevent  the use of protected  plant  materials 
for breeding  purposes.  In  contrast,  the  more broad-ranging utility patents not only 
prevent seed  increase via reproduction of the same variety, they also protect 
breeders against  unauthorized  use of  protected varieties for breeding and  research  
purposes.   
Particular way of the seed production is hybridization. Seed obtained from a 
hybrid crop (produced from different male and female parental varieties) does not 
have yield as high as the initial hybrid crop. Thus, breeders of hybrid crops have an 
effective non legal protection gains replanting by farmers.  High private investment 
in the crop breeding has tended to be concentrated in hybrids, in particular hybrid of 
maize and horticultural crops. For other crops, most breeding - related research until 
recently has been largely concentrated in the public sector, in agricultural experiment 
stations and Universities (WRIGHT et al., 2005).  
The development of genetic engineering of plants in the 1980s was 
accompanied  by  specific possibility of patentability of various  types  of  life forms, 
including those created by conventional breeding, and  particular sequences of 
genetic material or DNA such as genes, markers, and  promoters (which control  the  
expression of genes  in cells), which could be protected by utility patents. It must be 
stressed out that either positive or negative effect of life form patenting on 
humankind and environment are unpredictable. Utility patent protection is also 
available for novel methods of breeding and genetic engineering for new varieties   
produced   by use of new methods and for research tools. Novel plant could be 
protected by a utility patent on variety or on  its  genes, by a plant patent (XIA and 
BUCCOLA, 2005; KONSTANTINOV and MLADENOVIĆ 2006, 2007, 2009).  Novel  plant  
could  also be  patented  as  a product  of  the  novel method  by which  it was 
produced, such  as genetic engineering.  Utility patents protect the plant  breeder's  or  
inventor's  rights to control  the  use,  sale,  import, and reproduction of plants that 
have been patented or that incorporate patented material. Using utility patents, plant 
breeders can dictate the terms under which such plants can be used and could   
prevent others from using them for any subsequent breeding or for seed increase via 
replanting of the harvested seed. Many patented basic materials and methods for 
genetic engineering in agriculture were generated either in private corporations or in 
universities and are often licensed exclusively to private businesses (BOETTIGER and 
BENNETT, 2006). Biotechnology for an Open Society (http://www.bios.net/)  seeks to 
generate open-source development of suites of research tools for biotechnology 
innovation, unhindered by any patent thickets.  
Patenting in the agricultural biotechnology differs across entity type and across 
the time. As fast as patenting grew in broadly defined agricultural biotechnology, it 
grew even faster in the modern agricultural biotechnology. In the early years of the 
records there was almost no patenting in modern agricultural biotechnology.  In the 
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period from 1980 - 1984, modern agricultural biotechnology patents averaged  about 
3% of all agricultural biotechnology patents (GRILLICHES, 1990). By 1996-2000 
period patents averaged about 22% of all patents in agricultural biotechnology.  Even 
when patents obtained by modern gricultural biotechnology are extracted  from  the  
rest of the agricultural biotechnology sample, agricultural biotechnology patents still 
grew much more quickly than did total patents. What the patent data do confirm is 
the current importance of private sector in commercializing agricultural 
biotechnology, in particular plant -related technologies and modern agricultural 
biotechnology that relies more on the application of molecular biology (XIA and  
BUCCOLA,  2005).   
Universities may patent as a means to transfer technology to the private sector 
for further development, to attempt to generate licensing revenue, or perhaps to 
contribute to the regional economic development through the scientific parks. These 
motivations for the patenting by the Universities in particular are preferable in the 
literature rather than analyzed in any detail (JAFFE and LEMER, 2001). Research   
publications are the alternative measure, although not strictly comparable to patents, 
because they might represent somewhat more basic research than the research that 
results in patent applications (XIA and BUCCOLA, 2005). Universities however, do not 
appear to patent the near-market technologies such as plant cultivars.  Available data 
confirm that the US government only tends to patent in specific agricultural 
biotechnology research areas rather than broadly across all agricultural areas in 
which it performs research. This government patenting appears to be mainly in 
support  of  technology  transfer what is  important  in agricultural  biotechnology  in 
terms of patent counts, but with some exceptions, their patent  portfolio mimics  the 
portfolio held by  the  private sector (HEISEY, et al. 2005). Public - sector institutions, 
that patent, may do so for reasons differing from those motivating private firms 
(HENDERSON, et al., 1998; JAFFE and LEMER, 2001). Firms patent to protect their 
inventions, to develop strategic patent portfolios, and to generate licensing revenue 
(COHEN, et al., 2000, JAFFE, 2000). 
BUCOLA and XIA (2004) assessed the apparent decline in patent quality using 
citation based measures and proposed two hypotheses to explain this decline. First, a 
“technological hypothesis” proposed that agricultural biotech patents are moving 
downstream. Second, a “strategic hypothesis” suggested that firms are patenting 
more to maximize the value of their patent. They determined that the evidence may 
support both the technological and strategic hypotheses. 
Several examples have been documented of the struggle to obtain all the 
licenses that are necessary for introducing technologies into developing countries 
such as use of patents resting on the nutritionally enhanced “Golden Rice”. 
Numerous patents in the field of agricultural biotechnology turn out to have very 
little economic value, while “Golden Rice” prove to be extremely valuable 
(GRILICHES, 1990). Developed at the Universities in Switzerland and Germany it 
required a major commercial company to disentangle the thicket of rights and 
negotiate licenses for all these patents for their use for the poor.  No agreement was 
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reached because negotiations never started since patent holders did not show an 
interest to negotiate at all (BUCCOLA and XIA, 2004).  
Patents increasingly reduce the freedom to operate in plant breeding. 
Biotechnology companies are known to actively seek patent protection for their 
products. Knowledge created by the public Universities  and  research  Institutes is 
often protected   in spite of elementary human rights that  public resources should   
not be used  to enforce private rights. Patents on life and PBR (Plant Breeder s 
Right) facilitate enclosure and privatization of the global biological commons. This 
is inherently unjust and against the public interest. There are various strategies being 
used to study of Ethical Concerns about Plant Biotechnology. In Japan biology 
teachers considered there was more risk from genetic engineering than the ordinary 
public (MACER, 1992; 1994a, 1994b). There is however need for the education about 
computers, pesticides, nuclear power, biotechnology and genetic engineering. Both 
benefits and risks were cited by many respondents. Discovery itself may not be 
wrong, but how we use it or abuse it raises ethical questions.  
 
BIOETHICAL ISSUE OF LIFE FORM PATENTING 
Possibility to reach the balance between benefits and risk of science and   
technology depends on the level of society education of (MACER, 1990; 1992; 1994 
a, b).  Human population has not simplified opinion about the science and 
technology. Balancing between good and harm is indispensable  for  the  bioethical  
concern of the life and is indicator of bioethical maturity of the society.  
Comparative studies (HOBAN and KENDALL, 1992; MACER, 1995) showed  that  plant 
-plant gene  transfers  are  acceptable,  animal to animal  less, and  animal-plant or 
human-animal  gene transfers  were  least acceptable. 
The Group of Advisers on Ethical Aspects of Biotechnology to the 
European Commission (ECC, 1995) recommended food be labeled to indicate when 
its composition and characteristics have been substantially modified by genetic 
engineering techniques. There is substantial equivalence between the new food and a 
traditional counterpart (e.g. virus resistant plants produced by insertion of the viral 
coat protein, or herbicide tolerant plants produced by introducing a protein 
comparable to one already present in a plant but tolerant to a selective herbicide). 
According to OECD (1996) investigation: (i) there is substantial equivalence between 
the new  food  and   traditional counterpart, except for  the inserted trait (e.g. insect 
protected plants produced by the insertion  of  the  Bt  gene or disease resistant plants 
produced by the introduction  of a new protein); (ii) there is substantial equivalence 
between the new food and a traditional counterpart (e.g. virus resistant plants 
produced by insertion of the viral coat protein, or herbicide tolerant plants produced 
by introducing a protein comparable to one already present in a plant but tolerant to a 
selective herbicide); (iii) there is not substantial equivalence between the new food 
and a traditional counterpart (e.g. introduction of a gene or genes that encode a trait 
that significantly alters the plant for use in food or feed, such as production of a 
new oil or carbohydrate). If substantial equivalence is established they considered 
that the novel food be treated the same as the familiar one. If there was a new trait, 
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evaluation it should be done case - by case for the product of the gene. Anyhow, 
balance must be found between the right of consumers to information and the 
imposition of unnecessary information which may confuse people over what the 
major facts relevant to their diet are (NESTLE, 1996). Each state must take responsibility 
for any risk related to deliberate release of GM organisms into the environment (Van 
WAES, 2009). 
There are many unresolved legal and practical implications of the ethical 
issues when someone improves upon a variety that another has developed. Example 
is XA21 gene in rice. This gene is coding an important disease resistance, and 
based on earlier research by the International Rice Research Institute and its 
partners in India and Mali, have been patented by the University of California, 
Davis. After long negotiation University in Davis released the patent for 
development purposes and even did developed a benefit share mechanism for 
profits derived from the commercial use of the patent (http://www.genethics.org.)  
Many medicinal plants have been collected and selected by indigenous 
groups, local farmers and traditional medicinal healers. Modern approaches can 
identify the active ingredients and several patents have been issued to these 
companies. These are being challenged, but the issue needs further ethical resolution. 
The practical issues of royalty sharing also need to be resolved. It is quite important to 
have international approaches and support because food products are sold and 
transported across borders, and a ban in one country could be circumvented if a 
neighboring country approved its production (HOBAN and KENDAL, 1992).  
The issue of  Intellectual  Property  Rights (IPR)  in  public  research  could  
be  tackled  from different generic angles, including ethics - the role of science and 
academia in society and political economy http://www.cfra.org/resources/ 
issue_brief_patenting.htm).  
Public research organizations generally use patent protection as part of three 
strategies: maintaining their position at the frontier of science through maximizing 
their own freedom to operate, strengthening their position in public private 
partnerships, and obtaining a return on investment on their research through cash 
income.  
The Aims and Objectives of Plant Breeder's Rights Laws is to encourage 
plant breeders to produce  new  plant varieties, and  to benefit  society  with  access to 
new and  improved  plant varieties and assured food security.  Increased use of 
patents and the PBR, and decreased public investment in the plant breeding are 
reducing but not increasing the food and crop diversity. PBR is in many cases the 
way of the public resources privatization. Enclosing the global biological commons 
should not be permitted (GRAFF, et al., 2003a, b). It could be proposed that breeders 
be contracted by the community through governments to undertake certain essential 
work previously carried out by public sector breeders.  There are cases when PBR is 
placed on the variety hat has become available through a foreign aid  program  where 
local  breeders received the material for the purposes of assisting breeders or 
growers in other countries. Such bio piracy should not be rewarded and exemplary 
damages should apply (GENE ETHICS, 2007).  
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Strict liability should apply to gene contamination, especially where the 
pollen or seed of patented or PBR varieties transfer their genes into the genomes of 
conventional or organic crops. Plant breeders should not have  the greater rights  than  
people whose crops are contaminated  by  protected varieties. If criminal liability 
(with penalties of jail and fines) were to apply to alleged infringements of 
patents and PBR, they should  also  apply  to the inevitable contamination that   would  
ensure  from  the commercial release of (especially open-pollinated) GM and PBR  
plant varieties.   
Plant Breeders Right (PBR) law is inherently unfair since “inventiveness” is 
not a criterion for registering a plant variety under PBR. Invention is rightly a core 
criterion for a patent, which most GM companies use in preference to PBR to protect 
their varieties. Without an inventive step being required for PBR, biodiversity can 
be owned by a seed or any other company, with no innovation. This is classical 
biopiracy. It would be good to reward plant breeders to achieve its goals - 
development of the new plant varieties to meet the challenges of predicted tough 
environmental conditions and to ensure food security. Plant breeders have the 
option of suing to enforce their rights if they regard them as infringed and it seems 
as sufficient remedy (MACER, 1990).     
GENE ETHICS (2007) does not accept that living organisms should be the 
subject of monopoly ownership under the Patents or Plant Breeder's Rights Acts. 
Intellectual property rights should only be granted to encourage genuine inventions 
and should not apply to organisms originally found in nature. Plants are not 
inventions. PBR is doubly objectionable because, unlike patents, it does not apply 
the criteria of non-obviousness, inventiveness and reproducibility which must be 
met for the grant of a patent (http://www.genethics.org).  
Patent Office has issue as plant patents under the Plant Patent Act and   
utility patents under the Patent Act for the plants, under a Supreme Court decision 
that confirms the availability of such utility patents (J.E.M. 2001) despite the 
existence of more specialized statutes addressing intellectual property rights for 
specialized plants. It may be in certain cases that there are broader public policy 
reasons why it would  seem contrary to the public interest to grant patents to life forms 
( http://www.cfra.org/resources/issue_brief_patenting.htm.. ) 
Allowing patents on bacteria and seeds and the possibility of patenting their 
life forms raises ethical and moral questions (KONSTANTINOV and MLADENOVIĆ 
DRINIĆ 2006). It also raises questions relating to increasing consolidation in 
agriculture. How family farmers and ranchers are treated in such a legal and 
regulatory regime will go a long way in determining their future (Usefulness is a 
criterion for granting a U.S. patent).  Increasing of the biological material amount 
held privately rather than in the public domain as companies, devote additional 
resources to cost-effective patents. Public plant breeders will lose access to the 
germplasm.  Public research  being  directed  to a greater extent toward  satisfying  the  
desires of  the firms  that  purchase  the  rights  to the patents and to a lesser extent  
toward  the desires of farmers, ranchers and consumers. As a consequence it is 
greater control by firms holding patents of the crops grown from patented seed.  
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INSTEAD OF CONCLUSION 
The patenting of life forms raises public policy issues. Social and ethical issues require 
careful analysis and debate in order to evaluate and, possibly, to reform the basis for 
the issuing life form patents.  Bioethics combines risk assessment, the concept of 
avoiding harm, with an assessment of benefits, the concept of doing good or 
beneficence. It is important to ask whether there are any new risks compared to 
traditional plant breeding. Good example  are various risks in method of genetic 
engineering (recombinant DNA technology) application and life form patenting 
with obvious consequences: (i) the risk of unintentionally changing the genes of 
an organism; (ii) the risk of harming that organism; (iii) the risk of changing the 
ecosystem in which it was involved; (iv) the risk of harming the ecosystem; (v) the 
risk of change, or harm, to any other organism of that species or others, including 
human beings (who may even be the target of change). The extent to which a change 
is judged to be a subjective harm depends on human ethical values and permanent 
consideration whether nature should be “intransient” or in some way modified. This 
relates to the facts that this technology is at least unnatural if not dangerous. 
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I z v o d 
Razvoj novih biotehnologija zasnovanih na tehnologiji rekombinantne DNK, 
definisanih kao genetičko inženjerstvo, izazvao je značajne promene u načinu primene i 
komercijalizacije naučnih rezultata dobijenih u oblasti osnovnih istraživanja, posebno u 
poljoprivredi, medicini  i zaštiti životne sredine. Na hiljade patenata koji daju pravo na 
vlasništvo nad DNA sekvencama/genima je odobreno istraživačima u privatnom i 
javnom sektoru. Korišćenjem patentiranih gena, koji kontrolišu važne osobine 
(otpornost prema bolestima na pr.)  stvorene su i uvedene u proizvodnju nove sorte i 
hibridi najznačajnijih gajenih biljnih vrsta kao što su kukuruz, soja, pirinač kao i mnoge 
ukrasne biljke. Istraživači koji su vlasnici patenta gena imaju pravo na patentnu zaštitu i 
transgenih biljaka koje poseduju taj gen. Od posebnog značaja za istraživače u 
poljoprivredi, posebno u oblasti genetike i oplemenjivanja je mogućnost, korišćenjem 
genskih proba, karakterizacije genotipova  i dobijanje pouzdanih podataka o genetičkoj 
varijabilnosti , naročito u korišćenju kako u sopstvenim programima tako i u razmeni 
biološkog materijala sa drugim kolekcijama. Slobodna dostupnost tih proba je jedan od 
preduslova. Pitanje opravdanosti patentiranja sekvenci DNA/gena i njihovog korišćenja 
je neophodno ponovo otvoriti jer su patenti u nekom slučaju opravdani a unekom 
moraju da budu oprezno razmatrani..  Patentno pravo na sekvencu DNA/gen kao 
eksperimentalni material nije opravdano i treba ga obeshrabrivati. Najbolji način za 
ograničavanje zloupotrebe je strogo primena kriterijuma za patentiranje, posebno za 
pravo korišćenja patenata. Mnogo pravedniji, na etičkim principima zasnovan sistem 
proizvodnje hrane mora da ima ugrađena tri globalna cilja: poboljšanje kvaliteta života, 
zaštitu životne sredine i obezbeđenje zdravlja populacije sa akcentom na korišćenje 
hrane proizvedene od GMO. Jedan od pristupa ostvarenju ovih ciljeva je etičko i istinito 
obeležavanje hrane od GMO, jer potrošači imaju pravo izbora da li žele da koriste 
genetički modifikovanu hranu ili ne. Interesantan je primer i rizici koji proizilaze iz 
neograničene dostupnosti i korišćenja genetičkih resursa, njihova transformacija 
korišćenjem genetičkog inženjerstva, patentiranje “novog” genotipa – organizma a 
zatim njegova prodaja vlasniku korišćenog originalnog genotipa. Društvo ima obavezu 
podizanja nivoa kvaliteta hrane I standard življenja uz puno poštovanje etika na svakom 
stepenu razvoja. U radu su navedeni neki od slučajeva patentiranja koji ne zadovoljavaju 
osnovne etičke norme. 
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